Treatment-Resistant Depression (TRD)Depressive DisordersPTSDAnxiety DisordersEquity and Ethics

Integration in Psychedelic-Assisted Treatments: Recurring Themes in Current Providers’ Definitions, Challenges, and Concerns

Interviews with 30 integration therapists identified 19 reliably coded themes showing providers view integration as an ongoing, personalised bridge between the psychedelic experience and daily life, alongside common concerns about nonresponsive clients, unrealistic expectations, power differentials and commercialisation. These findings point to needs for standardisation of integration therapy, clearer public expectations, and formalised peer support for practitioners.

Authors

  • Michael Earleywine

Published

Journal of Humanistic Psychology
individual Study

Abstract

Integration therapy, an integral part of psychedelic-assisted treatment, usually includes sessions devoted to making meaning of relevant psychedelic experiences after subjective effects have subsided. As the psychedelic renaissance continues, offers for this integration therapy have proliferated. In the present project, semi-structured interviews with 30 integration therapists focused on definitions of integration as well as challenges and concerns that they associated with the practice. A mixed-methods approach revealed 19 themes that coders identified reliably. Prevalent themes included expressing concern about nonresponsive clients, defining integration as a bridge between the psychedelic experience and daily life, and apprehensions about the commercialization of psychedelic psychotherapy. Interviewees viewed integration as a process that begins prior to the administration of substances, never ends, makes sense of the psychoactive experience, creates behavioral change, is personalized, and makes the individual whole. Most participants also discussed issues related to client resistance, unrealistic expectations of psychedelic psychotherapy, problems associated with power differentials, the importance of an integration therapist’s connection to other service providers, and the need for self-care. These data might help the standardization of integration therapy, inform lay impressions of the process, and help generate hypotheses for continued research on this aspect of psychedelic-assisted treatment. These data also suggest that psychedelic integration practitioners would appreciate regular support from a community of like-minded colleagues.

Available with Blossom Pro

Research Summary of 'Integration in Psychedelic-Assisted Treatments: Recurring Themes in Current Providers’ Definitions, Challenges, and Concerns'

Introduction

Clinical research has renewed interest in psychedelic-assisted treatments, which commonly combine preparation, guided administration, and post‑experience integration. Earlier trials cited by the authors indicate therapeutic promise for substances such as psilocybin (for anxiety and treatment‑resistant depression) and MDMA (for PTSD). Practices vary widely across settings: some protocols emphasise an on‑site guide during acute effects, others accommodate solo experiences for legal or pragmatic reasons, and integration approaches draw on diverse theoretical traditions ranging from psychodynamic formulations to evidence‑based therapies and shamanic or creative practices. Earleywine and colleagues identify a gap in the empirical literature: despite the centrality of integration to psychedelic therapy, its components, prevailing definitions among practitioners, and the practical challenges and ethical concerns therapists encounter are not well characterised. The present study therefore aimed to interview experienced integration providers to map recurring definitions of integration and to catalogue the challenges and concerns they perceive, with the hypothesis that interview data could clarify current practice and that perceptions of challenges would relate to practitioners' definitions of integration.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (15)

Papers cited by this study that are also in Blossom

Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism

Bogenschutz, M. P., Forcehimes, A. A. · Journal of Humanistic Psychology (2016)

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)

The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis

Goldberg, S. B., Pace, B. T., Nicholas, C. R. et al. · Psychiatry Research (2020)

Psychedelic Harm Reduction and Integration: A Transtheoretical Model for Clinical Practice

Palhano-Fontes, F., Gorman, I., Nielson, E. M. et al. · Frontiers in Psychology (2021)

A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis

Illingworth, B. J. G., Lewis, D. J., Lambarth, A. T. et al. · Journal of Psychopharmacology (2020)

39 cited
Human hallucinogen research: guidelines for safety

Johnson, M. W., Richards, W. A., Griffiths, R. R. · Journal of Psychopharmacology (2008)

Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts

Noorani, T., Garcia-Romeu, A., Swift, T. C. et al. · Journal of Psychopharmacology (2018)

Combining Psychedelic and Mindfulness Interventions: Synergies to Inform Clinical Practice

Payne, J. E., Chambers, R., Liknaitzky, P. · ACS Pharmacology and Translational Science (2021)

55 cited
Ethical and legal issues in psychedelic harm reduction and integration therapy

Pilecki, B., Luoma, J. B., Bathje, G. J. et al. · Harm Reduction Journal (2021)

Show all 15 references
Integrating Psychedelic Medicines and Psychiatry: Theory and Methods of a Model Clinic

Sloshower, J. A. · Plant Medicines Healing and Psychedelic Science (2018)

Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame

Sloshower, J., Guss, J., Krause, R. et al. · Journal of Contextual Behavioral Science (2020)

Psychedelics and health behaviour change

Teixeira, P. J., Johnson, M. W., Timmermann, C. et al. · Journal of Psychopharmacology (2021)

Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example

Wagner, A. C., Mithoefer, M. C., Mithoefer, A. T. et al. · Journal of Psychoactive Drugs (2019)

Cited By (7)

Papers in Blossom that reference this study

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.